Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug targets inflammation in heart and kidney patients

NCT ID NCT06675175

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new drug called AZD4144 in 29 people who have both heart disease and chronic kidney disease. The main goal was to see if the drug is safe and if it lowers certain markers of inflammation in the blood. The study compared the drug against a placebo over 4 weeks.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AZD4144
What this could lead to
If successful, this could point toward a new way to reduce inflammation in people with both heart and kidney disease.
What could go wrong
This is a very early Phase 1 trial with only 29 people, so it is mainly checking safety, not yet proving the drug works. Many early-stage drugs do not move forward.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

29 people

The number who actually took part.

Started

Dec 2024

Finished

Oct 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Participants with established ASCVD history of one or more of the following 1. Prior Myocardial infarction (MI) (\>60 days from index event) or coronary revascularization procedure like coronary stenting or Coronary artery bypass graft (CABG) 2. Prior ischemic stroke (\>60 days from index event) 3. Symptomatic Peripheral Arterial Disease * Chronic kidney disease defined as eGlomular filtration rate (eGFR) ≥ 30 to \< 60 mL/min/1.73 m2 * Serum hsCRP \> 2 mg/L * Body mass index ≥ 18 to ≤ 45 kg/m2 * All females must have a negative pregnancy test at the Screening Visit and at the randomization visit 1. Sexually active male participants with partner of childbearing potential must adhere to the contraception methods 2. Females of childbearing potential must not be lactating and if heterosexually active must agree to use an approved method of highly effective contraception 3. Females of non-childbearing potential must be confirmed at the Screening visit Key Exclusion Criteria: * History of malignancy within the last 5 years * History of MI, coronary revascularization, stroke or revascularization for peripheral arterial disease in the 60 days prior to Screening * Active systemic infection within 30 days * Clinically significant active and chronic infections within 60 days prior to randomization * Clinically significant recurrent infection (≥ 2× during the last 12-month period). * Renal transplant participants, participants on dialysis, and those with a history of acute kidney injury in the past 12 month

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atherosclerotic cardiovascular disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

atherosclerosis atherosclerotic cardiovascular disease chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atherosclerotic cardiovascular disease Chronic kidney disease

Contacts and locations

Locations

  • Research Site

    Glendale, California, 91203, United States

  • Research Site

    Daytona Beach, Florida, 32117, United States

  • Research Site

    Jacksonville, Florida, 32216, United States

  • Research Site

    Miami, Florida, 33125, United States

  • Research Site

    Port Orange, Florida, 32127, United States

  • Research Site

    Tampa, Florida, 33603, United States

  • Research Site

    Farmington Hills, Michigan, 48334, United States

  • Research Site

    The Bronx, New York, 10455, United States

  • Research Site

    Sherman, Texas, 75092, United States

  • Research Site

    Pleven, 5800, Bulgaria

  • Research Site

    Sofia, 1527, Bulgaria

  • Research Site

    Gyöngyös, 3200, Hungary

  • Research Site

    Kistarcsa, 2143, Hungary

  • Research Site

    Bucharest, 11658, Romania

  • Research Site

    Cluj-Napoca, 400006, Romania

More trials for these conditions

Other studies related to the condition(s) this trial covers.